Consolidated statements of cash flows 2016 2015 2014 Years ended December 31 $M $M $M Cash flows from operating activities: Net income 327.4 1,303.4 3,405.5 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 1,466.3 637.2 407.3 Share-based compensation 318.5 100.3 97.0 Amortization of deferred financing costs 125.5 Change in fair value of contingent consideration 11.1 149.9 14.7 Unwind of inventory fair value step-up 1,118.0 31.1 91.9 Impairment of intangible assets 8.9 643.7 190.3 Movement in deferred taxes 594.6 198.2 14.3 Write-down of PP&E 92.4 Other, net 31.4 27.9 Changes in operating assets and liabilities: Increase in accounts receivable 701.7 211.4 66.1 Increase in sales deduction accruals 288.3 97.6 107.6 Increase in inventory 255.8 63.2 25.3 Decrease increase in prepayments and other assets 198.4 37.2 42.4 Increase in accounts and notes payable and other liabilities 621.6 109.2 5.3 Net cash provided by operating activities 2,658.9 2,337.0 4,228.4 Cash flows from investing activities: Movements in restricted cash 62.8 32.0 32.6 Purchases of subsidiary undertakings and businesses, net of cash acquired 17,476.2 5,553.4 4,104.4 Purchases of non-current investments and PP&E 648.7 124.2 100.1 Proceeds from short-term investments 67.0 57.8 Proceeds received on sale of product rights 10.9 17.5 127.0 Proceeds from disposal of non-current investments and PP&E 0.9 18.7 21.5 Other, net 41.9 13.5 0.2 Net cash used in investing activities 18,092.2 5,619.9 4,030.6 The accompanying notes are an integral part of these Consolidated Financial Statements.
Shire Annual Report 2016 129 Other information Financial statements Governance Strategic report Consolidated statements of cash flows continued 2016 2015 2014 Years ended December 31 $M $M $M Cash flows from financing activities: Proceeds from revolving line of credit, long-term and short-term borrowings 32,443.4 3,760.8 2,310.8 Repayment of revolving line of credit, long-term and short-term borrowings 16,404.3 3,110.9 1,461.8 Repayment of debt acquired through business combinations 551.5 Proceeds from ViroPharma call options 346.7 Payment of dividend 171.3 134.4 121.2 Debt issuance costs 172.3 24.1 10.2 Contingent consideration payments 8.0 101.2 15.2 Proceeds from exercise of options 129.0 16.6 17.4 Other, net 9.3 32.2 39.5 Net cash provided by financing activities 15,825.8 439.0 554.5 Effect of foreign exchange rate changes on cash and cash equivalents 0.8 3.0 9.3 Net increase decrease in cash and cash equivalents 393.3 2,846.9 743.0 Cash and cash equivalents at beginning of period 135.5 2,982.4 2,239.4 Cash and cash equivalents at end of period 528.8 135.5 2,982.4 Supplemental information associated with continuing operations: 2016 2015 2014 Years ended December 31 $M $M $M Interest paid 284.0 20.0 14.5 Income taxes paid received 431.0 69.0 194.4 Receipt of break fee 1,635.4 For stock issued as purchase consideration on the Baxalta acquisition related to non-cash investing activities, see Note 4, Business Combinations.
The accompanying notes are an integral part of these Consolidated Financial Statements.
